Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of zalfermin, cagrilintide, and semaglutide alone or combined for alcohol-related liver disease
NL-OMON59347Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nn9500, cagrilintide and semaglutide in alcoholic liver disease (ALD) (6 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Enhanced Liver Fibrosis (ELF). Started Aug 2024; status: completed.
02
Drugs
03
Conditions
alcoholic liver disease (ALD)
Beyond the preview
Go deeper on NL-OMON59347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59347.